Kathy D. Miller, MD serves on the editorial boards of Clinical Breast Cancer and Breast Disease. She is a recipient of a Career Development Award from the American Society of Clinical Oncology. Dr. Miller’s career combines both laboratory and clinical research. She honed her ability to coordinate multi-center trials as principal investigator for the pivotal phase III trial of capecitabine +/- bevacizumab, the first phase III trial of a novel anti-angiogenic agent in breast cancer. She is currently the principal investigator of a 700+ patient phase III trial (E2100) in the Eastern Cooperative Oncology Group.